Tokyo-bases R-tech Submits ANDA To U.S. FDA For Glaucoma Drug
This article was originally published in PharmAsia News
Executive Summary
R-Tech Ueno submitted an abbreviated new drug application to U.S. FDA for latanoprost eye drops for glaucoma and ocular hypertension